Medicare Enrolled
Dr. Frank Mori, M.D.
Hematology & Oncology · La, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Mori from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mori?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Mori
Dr. Frank Mori is a hematology & oncology specialist in La, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Mori performed 62,765 Medicare services across 1,503 unique beneficiaries.
Between the years covered by Open Payments, Dr. Mori received a total of $35,103 from 74 pharmaceutical and/or device companies across 1648 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mori is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 12% volume in CA
$35,103 industry payments
Medicare Practice Summary
Medicare Utilization ↗62,765
Medicare services
Top 12% in CA for hematology & oncology
1,503
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,303 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
40,500 | $1 | $1 |
| Denosumab injection (Prolia/Xgeva) | 11,340 | $18 | $29 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
6,001 | $6 | $10 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,124 | $107 | $172 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
796 | $0 | $0 |
| Anti-nausea injection (Aloxi/palonosetron) | 700 | $1 | $1 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
425 | $12 | $30 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
348 | $27 | $39 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
324 | $42 | $62 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
218 | $63 | $80 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
157 | $121 | $177 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
141 | $1 | $2 |
| New patient office visit, complex (60-74 min) | 127 | $182 | $320 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
122 | $46 | $128 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
94 | $144 | $300 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
76 | $21 | $45 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
68 | $84 | $160 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
61 | $59 | $81 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
55 | $26 | $40 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
47 | $24 | $40 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
22 | $35 | $65 |
| Heparin sodium injection, per 1000 units An injection of heparin sodium, a blood thinner, administered in units of 1000. |
19 | $0 | $0 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
65.4% high complexity
31.1% medium
3.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$35,103
Total received (2018-2024)
Avg $5,015/year across 7 years
Top 15% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
74
Companies
1,648
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$34,267 (97.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$836 (2.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$5,988
2023
$6,171
2022
$5,338
2021
$4,854
2020
$3,491
2019
$4,371
2018
$4,890
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$719
Celgene Corporation
$464
Incyte Corporation
$414
ABBVIE INC.
$413
Janssen Biotech, Inc.
$400
Exelixis Inc.
$325
EMD Serono, Inc.
$320
Gilead Sciences, Inc.
$293
E.R. Squibb & Sons, L.L.C.
$235
Lilly USA, LLC
$229
Bayer Healthcare Pharmaceuticals Inc.
$212
PFIZER INC.
$211
Novartis Pharmaceuticals Corporation
$200
Karyopharm Therapeutics Inc.
$168
Takeda Pharmaceuticals U.S.A., Inc.
$156
Astellas Pharma US Inc
$155
BeiGene USA, Inc.
$154
Genentech USA, Inc.
$120
ADC Therapeutics America, Inc.
$120
Daiichi Sankyo Inc.
$111
Ipsen Biopharmaceuticals, Inc
$72
Adaptive Biotechnologies Corporation
$64
Blueprint Medicines Corporation
$64
Mirati Therapeutics, Inc.
$63
Boehringer Ingelheim Pharmaceuticals, Inc.
$47
Regeneron Healthcare Solutions, Inc.
$44
JAZZ PHARMACEUTICALS INC.
$33
Merck Sharp & Dohme LLC
$33
PharmaEssentia USA Corporation
$30
GENZYME CORPORATION
$30
Alnylam Pharmaceuticals Inc.
$27
SOBI, INC
$25
Kite Pharma, Inc.
$17
Sirtex Medical Inc
$16
Top 3 companies account for 26.7% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$3,117
AstraZeneca Pharmaceuticals LP
$2,982
Amgen Inc.
$2,120
Astellas Pharma US Inc
$1,829
Novartis Pharmaceuticals Corporation
$1,769
Genentech USA, Inc.
$1,733
Incyte Corporation
$1,726
Celgene Corporation
$1,624
PFIZER INC.
$1,408
Janssen Biotech, Inc.
$1,290
Bayer HealthCare Pharmaceuticals Inc.
$1,214
Lilly USA, LLC
$1,137
Pharmacyclics LLC, An AbbVie Company
$1,024
Seagen Inc.
$1,017
Exelixis Inc.
$903
Gilead Sciences, Inc.
$895
Karyopharm Therapeutics Inc.
$819
EMD Serono, Inc.
$816
Takeda Pharmaceuticals U.S.A., Inc.
$786
GENZYME CORPORATION
$543
Bayer Healthcare Pharmaceuticals Inc.
$500
Teva Pharmaceuticals USA, Inc.
$438
ABBVIE INC.
$413
Merck Sharp & Dohme Corporation
$367
BeiGene USA, Inc.
$347
Boehringer Ingelheim Pharmaceuticals, Inc.
$341
Blueprint Medicines Corporation
$271
Daiichi Sankyo Inc.
$238
Mirati Therapeutics, Inc.
$231
Alexion Pharmaceuticals, Inc.
$212
TESARO, Inc.
$199
Ipsen Biopharmaceuticals, Inc
$198
Regeneron Healthcare Solutions, Inc.
$195
Merck Sharp & Dohme LLC
$192
Pharmacyclics LLC, an AbbVie Company
$172
EISAI INC.
$142
Puma Biotechnology, Inc.
$135
MorphoSys, US Inc.
$129
ADC Therapeutics America, Inc.
$120
INSYS Therapeutics Inc
$106
Eisai Inc.
$88
Kite Pharma, Inc.
$84
Myriad Genetic Laboratories, Inc.
$78
Taiho Oncology, Inc.
$77
ImmunoGen, Inc.
$75
AbbVie Inc.
$70
Adaptive Biotechnologies Corporation
$64
AVEO Pharmaceuticals, Inc.
$56
JAZZ PHARMACEUTICALS INC.
$55
Otsuka America Pharmaceutical, Inc.
$53
GlaxoSmithKline, LLC.
$51
Stemline Therapeutics Inc.
$51
SOBI, INC
$49
PharmaEssentia USA Corporation
$47
Kyowa Kirin, Inc.
$47
Spectrum Pharmaceuticals Inc.
$46
Agios Pharmaceuticals, Inc.
$46
Rigel Pharmaceuticals, Inc.
$39
Heron Therapeutics, Inc.
$30
Advanced Accelerator Applications
$28
Alnylam Pharmaceuticals Inc.
$27
Shire North American Group Inc
$26
Helsinn Therapeutics (U.S.), Inc.
$25
TAIHO ONCOLOGY, INC.
$23
Acrotech Biopharma LLC
$19
EUSA Pharma (US) LLC
$19
Verastem, Inc.
$18
Global Blood Therapeutics, Inc.
$18
Epizyme, Inc.,
$18
Tactile Systems Technology Inc
$17
Sirtex Medical Inc
$16
West Therapeutics Development, LLC
$14
MEDIVATION FIELD SOLUTIONS LLC
$14
AbbVie, Inc.
$13
Top 3 companies account for 23.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALUNBRIG · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · BAVENCIO · BENDEKA · BESREMI · BOSULIF · BRUKINSA · Bavencio · CABLIVI · CABOMETYX · CALQUENCE · CHANTIX · CINVANTI · CYRAMZA · Cabometyx · Copiktra · DARZALEX · Doptelet · ELAHERE · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · EXKIVITY · Elahere · Enhertu · FOLOTYN · FOTIVDA · FRUZAQLA · Fabhalta · Flexitouch Plus · Folotyn · GAVRETO · GAZYVA · GILOTRIF · GIVLAARI · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Idhifa · Imbruvica · Inrebic · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lutathera · MEKINIST · MONJUVI · MVASI · MYRISK · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · ONUREG · OPDIVO · OPDUALAG · OXBRYTA · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · Padcev · Perjeta · Pomalyst · Poteligeo · Prolia · REBLOZYL · RYBREVANT · RYDAPT · Revlimid · SARCLISA · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SUBSYS · SUSTOL · SUTENT · SYNDROS · Somatuline Depot · Stivarga · Subsys · Sylvant · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · Tecentriq · Trodelvy · ULTOMIRIS · VELCADE · VENCLEXTA · VERZENIO · VONJO · VOTRIENT · VPRIV · VYXEOS · Vectibix · Vemlidy · Venclexta · Vyloy · XALKORI · XGEVA · XOSPATA · XPOVIO · XTANDI · Xofigo · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
357
Per 100K population
3.6
County median income
$87,760
Nearest hospital
CEDAR-SINAI MARINA DEL REY HOSPITAL
3.1 mi
3.1 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Mori is a mixed practice specialist, with above-average Medicare volume (top 12% in CA), with low-engagement industry engagement in the top 15% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Mori experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Mori performed 40,500 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mori receive payments from pharmaceutical companies?
Yes. Dr. Mori received a total of $35,103 from 74 companies across 1,648 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mori's costs compare to other hematology & oncology specialists in La?
Dr. Mori's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mori) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in La
Browse hematology & oncology specialists in La ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology